Analysis Showing LUPKYNIS is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024 (Businesswire) - May 14, 2024 - "Aurinia Pharmaceutical...today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program....LUPKYNIS is substantially below ICER's willingness-to-pay threshold of $150,000 in adult patients with active LN. The incremental cost of the treatment was $88,076 per quality adjusted life year (QALY) and $77,643 per equal value of life year gained (evLYG) in patients with active LN....The Enlight-LN registry, designed to characterize the real-world effectiveness profile and usage patterns of LUPKYNIS, is enrolling patients in the US."
Clinical data • HEOR • Lupus Nephritis
|